Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  monoclonal antibody conjugate
Results 1-25 of 1576 for your search:
Start Over
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 99
Trial IDs: M15-394, NCI-2016-00469, 2015-001645-84, NCT02565758
Chimeric Fibril-Reactive Monoclonal Antibody 111F4 in Treating Patients with Relapsed or Refractory Amyloid Light-Chain Amyloidosis
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: AAAM5108, NCI-2014-01515, IRB-AAAM5108, NCT02245867
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-467, NCI-2015-01096, 2014-002609-39, NCT02462525
A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-237, NCI-2014-00926, 2014-003154-14, NCT02099058
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: EC1456-01, NCI-2016-00552, NCT01999738
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SGNLVA-001, NCI-2013-02245, NCT01969643
Glembatumumab Vedotin in Treating Patients with Recurrent or Refractory Osteosarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 49 years
Trial IDs: AOST1521, NCI-2015-01037, NCT02487979
A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CDX011-05, NCI-2015-00448, NCT02302339
Glembatumumab Vedotin in Treating Patients with Metastatic or Locally Recurrent Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9855, NCI-2015-00159, NCT02363283
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PrE0504, NCI-2016-00523, CDX011-54, NCT02713828
Humanized Monoclonal Antibody 3F8 in Treating Patients with High-Risk Neuroblastoma and GD2-Positive Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 1 to 21
Trial IDs: 11-009, NCI-2011-03341, NCT01419834
Brentuximab Vedotin Maintenance after Donor Stem Cell Transplant in Treating Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 2013-0351, NCI-2014-01593, NCT02169505
Conjugated Estrogens/Bazedoxifene in Treating Patients with Ductal Carcinoma in Situ Undergoing Surgery
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: NU 15B06, NCI-2016-00066, STU00202100, NCT02694809
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GEN702, NCI-2015-01770, NCT02552121
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29365, NCI-2015-00293, 2014-001361-28, NCT02257567
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AGS15E-13-1, NCI-2013-02093, NCT01963052
Brentuximab Vedotin, Bendamustine Hydrochloride, and Rituximab in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1507953455, NCI-2015-01468, T502a, NCT02623920
Monoclonal Antibody Therapy in Treating Younger Patients with Relapsed or Refractory Neuroblastoma, Osteosarcoma, or Melanoma
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 21
Trial IDs: SJGD2, NCI-2011-01150, ED FDN, NCT00743496
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: ADCT-402-102, NCI-2016-00226, NCT02669264
Anti-EGFR Monoclonal Antibody Mixture Sym004 in Treating Patients with Recurrent Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00063483, NCI-2015-01931, NCT02540161
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: APX005M-001, NCI-2015-01531, NCT02482168
Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Recurrent Osteosarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 to 40
Trial IDs: 15-096, NCI-2015-01423, NCT02502786
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Relapsed or Refractory High-Risk Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 1
Trial IDs: 12-230, NCI-2013-00007, NCT01757626
Start Over